What’s more, GDI2 could also act as a prognostic biomarker to correlate HCC patients with high GDI2 expression to poor prognosis, including poor overall survival (OS), poor progression-free interval (PFI), and poor disease-specific survival (DSS) (*P < 0.05) (Figure 5). The gene discussed is GDI2; the disease is hepatocellular carcinoma.